Copyright
©The Author(s) 2023.
World J Clin Cases. Sep 26, 2023; 11(27): 6398-6406
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6398
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6398
Table 1 Patient characteristics according to age group
Variable | ≤ 35 yr group (n = 78), n (%) | > 35 yr group (n = 353), n (%) | P value |
BMI | 0.064 | ||
≤ 25 | 56 (71.8) | 211 (59.7) | |
> 25 | 22 (28.2) | 142 (40.23 | |
Clinical tumor stage | 0.187 | ||
cT1 | 8 (10.26) | 15 (4.25) | |
cT2 | 36 (46.15) | 184 (52.12) | |
cT3 | 26 (33.33) | 120 (33.99) | |
cT4 | 8 (10.26) | 34 (9.63) | |
Clinical node stage | 0.237 | ||
cN1 | 14 (17.95) | 96 (27.20) | |
cN2 | 40 (51.28) | 162 (45.89) | |
cN3 | 24 (30.77) | 95 (26.91) | |
Pathologic tumor stage | 0.101 | ||
ypT0-is | 15 (19.23) | 34 (9.63) | |
ypT1 | 23 (29.49) | 116 (32.86) | |
ypT2 | 25 (32.05) | 111 (31.44) | |
ypT3 | 15 (19.23) | 84 (23.80) | |
ypT4 | 0 (0.00) | 8 (2.27) | |
Pathologic node stage | 0.336 | ||
ypN0 | 25 (32.05) | 110 (31.16) | |
ypN1 | 30 (38.46) | 111 (31.44) | |
ypN2 | 18 (23.08) | 86 (24.36) | |
ypN3 | 5 (6.41) | 46 (13.03) | |
Lymphovascular invasion | 0.739 | ||
Present | 38 (48.72) | 168 (47.59) | |
Absent | 32 (41.03) | 157 (44.48) | |
Unknown | 8 (10.26) | 28 (7.93) | |
Surgery | 0.195 | ||
Breast conserving | 43 (55.13) | 166 (47.03) | |
Mastectomy | 35 (44.87) | 187 (52.97) | |
Nuclear grade | 0.697 | ||
Low | 11 (14.10) | 37 (10.48) | |
Intermediate | 32 (41.03) | 165 (46.74) | |
High | 27 (34.62) | 121 (34.28) | |
Unknown | 8 (10.26) | 30 (8.50) | |
Radiation therapy | 0.642 | ||
Yes | 75 (96.15) | 335 (94.90) | |
No | 3 (3.85) | 18 (5.10) | |
GnRH agonist | < 0.001 | ||
Yes | 22 (52.4) | 20 (11.2) | |
No | 20 (47.6) | 158 (88.8) |
Table 2 Patient characteristics according to gonadotropin-releasing hormone agonist treatment in equal to or younger than 35 years patients
Variable | GnRH agonist (n = 30), n (%) | No. of GnRH agonist (n = 48), n (%) | P value |
BMI | 0.999 | ||
≤ 25 | 25 (83.33) | 40 (83.33) | |
> 25 | 5 (16.67) | 8 (16.67) | |
Clinical tumor stage | 0.150 | ||
cT1 | 2 (6.67) | 6 (12.50) | |
cT2 | 13 (43.33) | 23 (47.92) | |
cT3 | 14 (46.67) | 12 (25.00) | |
cT4 | 1 (3.33) | 7 (14.58) | |
Clinical node stage | 0.185 | ||
cN1 | 8 (26.67) | 6 (12.50) | |
cN2 | 12 (40.00) | 28 (58.33) | |
cN3 | 10 (33.33) | 14 (29.17) | |
Pathologic tumor stage | 0.706 | ||
ypT0-is | 7 (23.33) | 8 (16.67) | |
ypT1 | 8 (26.67) | 15 (31.25) | |
ypT2 | 8 (26.67) | 17 (35.42) | |
ypT3 | 7 (23.33) | 8 (16.67) | |
ypT4 | 0 (0.00) | 0 (0.00) | |
Pathologic node stage | 0.061 | ||
ypN0 | 9 (30.00) | 16 (33.33) | |
ypN1 | 10 (33.33) | 20 (41.67) | |
ypN2 | 7 (23.33) | 11 (22.92) | |
ypN3 | 4 (13.33) | 1 (2.08) | |
Lymphovascular invasion | 0.754 | ||
Present | 13 (43.33) | 25 (52.08) | |
Absent | 14 (46.67) | 18 (37.50) | |
Unknown | 3 (10.00) | 5 (10.42) | |
Surgery | 0.472 | ||
Breast conserving | 15 (50.00) | 28 (58.33) | |
Mastectomy | 15 (50.00) | 20 (41.67) | |
Nuclear grade | 0.984 | ||
Low | 4 (13.33) | 7 (14.58) | |
Intermediate | 13 (43.33) | 19 (39.58) | |
High | 10 (33.33) | 17 (35.42) | |
Unknown | 3 (10.00) | 5 (10.42) | |
Radiation therapy | 0.555 | ||
Yes | 28 (93.33) | 47 (97.92) | |
No | 2 (6.67) | 1 (2.08) |
- Citation: Choi HJ, Lee JH, Jung CS, Ryu JM, Chae BJ, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE, Jung YJ, Kim HY. Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy. World J Clin Cases 2023; 11(27): 6398-6406
- URL: https://www.wjgnet.com/2307-8960/full/v11/i27/6398.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i27.6398